David Kaplan

23PUBLICATIONS
183CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Legal institutions (incl. courts and justice systems)HaematologyCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

|Apr 27, 2026
Outcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria-A Single-center Experience.

|Apr 14, 2026
Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration.

Shalini Bansal, Priya Amin, Courtney Williamson

|Sep 26, 2025
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.

Marijana Vujkovic, David E Kaplan, Jonas Ghouse

|Oct 26, 2024
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

David E Kaplan, Ruoding Tan, Cheryl Xiang

|Sep 23, 2024
Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.

Peiman Habibollahi, Alexey Gurevich, James Z Hui

Pageof 4

Frequent Collaborators

5 joint publications

Marijana Vujkovic

4 joint publications

Benjamin F Voight

4 joint publications

Julie Lynch

3 joint publications

Philip Tsao